

Fighting obesity made easy

**DC CORRESPONDENT
KOCHI, MAY 24**

The Central Marine Fisheries Research Institute (CMFRI) has commercialized its recently-developed nutraceutical product named Cadalmin™ Antihypercholesterolemic extract (Cadalmin™ ACE) for reducing obesity and cholesterol. The CMFRI gave the exclusive license to the VLCC, a leading Indian MNC in wellness and obesity management for using the technology for commercial production and marketing of the product.

Dr A. Gopalakrishnan, director of CMFRI, signed a license agree-



ment with Sandeep Ahuja, director of the VLCC Group and Dr A. H. Zaidi, executive vice-president (R & D) of the firm.

CMFRI developed the anti-obesity nutraceutical product using natural marine bioactive ingredients from selected seaweeds after years of intensive research and the product was found to be effective in combating dyslipidemia and obesity.

'CADALMIN™ ACE'

■ **CMFRI-developed product helps reduce obesity and cholesterol. Institute has given the license to VLCC, an Indian MNC.**

(Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids in the blood).

The bioactive principles contained in Cadalmin™ ACE inhibit various enzymes like hydroxymethyl glutaryl coenzyme, reductase and various target receptors, which are responsible for causing obesity and dyslipidemia.

According to Dr Gopalakrishnan, Cadalmin™ ACE provides a unique blend of 100 per cent natural marine bioactive ingredients from selected seaweeds with an eco-friendly 'green technology', which is currently under patent. "The product has been proved to be devoid of any side effects following long-term oral administration of the tablets as established by detailed pre-clinical trials. The nutraceutical product is prepared from seaweeds, which are known for their extraordinary medicinal properties and are commonly available in the Indian coastal waters", he said.